SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- A milestone event unfolds today with the announcement of the Digital In Vivo Alliance (DIVA), a precompetitive independent consortium of pharmaceutical leaders, innovative biotechs, and the public sector. This collaboration brings together AbbVie, BioMarin, Calico Life Sciences, Novartis, and The Jackson Laboratory as the founding members.

2023年10月19日，旧金山/PRNewswire/-随着数字体内联盟（DIVA）的宣布，这一里程碑事件今天展开，DIVA是一个由制药领导者，创新生物技术和公共部门组成的竞争前独立联盟。这项合作将AbbVie，BioMarin，Calico Life Sciences，Novartis和Jackson Laboratory召集为创始成员。

DIVA has the mission to collaboratively advance digital biomarkers for preclinical in vivo research through their development, validation, adoption, and regulatory acceptance..

DIVA的使命是通过开发，验证，采用和监管接受，共同推进用于临床前体内研究的数字生物标志物。。

Continue Reading

继续阅读

Digital In Vivo Alliance

数字体内联盟

Digital In Vivo Alliance members work together non-competitively, for the purpose of exploring preclinical applications of AI-enabled digital biomarkers from home cage-compatible technologies. This collaborative approach serves to accelerate the understanding and integration of digital biomarkers in preclinical models, fortifying our shared vision of enabling novel therapies through the adoption of digital biomarkers in AI-enhanced in vivo research.

数字体内联盟成员非竞争性地合作，目的是从家庭笼兼容技术探索启用AI的数字生物标志物的临床前应用。这种协作方法有助于加速数字生物标志物在临床前模型中的理解和整合，通过在AI增强的体内研究中采用数字生物标志物，加强我们实现新疗法的共同愿景。

'Our values are Collaboration, Scientific Excellence, Optimized Animal Welfare and Patient Impact,' announces Brian Berridge, DVM, PhD, an industry expert and DIVA's Chair. .

行业专家兼DIVA主席Brian Berridge博士宣布：“我们的价值观是合作，科学卓越，优化动物福利和患者影响。 .

'With the advent of sophisticated AI and machine learning, an opportunity has emerged to enhance preclinical studies utilizing computer vision with advanced monitoring of rodents in their home cage environment, providing a dynamic and holistic approach to digital biomarker development.' - says Dr. Berridge - 'Our members are collaboratively developing capabilities that promise greater operational efficiencies, increased translational relevance, and increased reproducibility of in vivo studies.

“随着复杂的人工智能和机器学习的出现，出现了一个机会，利用计算机视觉加强临床前研究，在家庭笼养环境中对啮齿动物进行先进监测，为数字生物标志物开发提供动态和整体的方法。”Berridge博士说：“我们的成员正在合作开发能够提高运营效率，提高翻译相关性和提高体内研究可重复性的能力。

This results in greater value to drug developers and patients.'.

这给药物开发者和患者带来了更大的价值。

These founding members are the nucleus of a growing community of digital biomarker developers and users. DIVA has developed a foundational set of behavioral and physiological biomarkers that are being applied to a variety of in vivo models, including dermatitis, epilepsy, neuromotor disease, respiratory disease, and toxicity assessment.

这些创始成员是数字生物标志物开发人员和用户不断增长的社区的核心。DIVA开发了一套基本的行为和生理生物标志物，可应用于各种体内模型，包括皮炎，癫痫，神经运动疾病，呼吸系统疾病和毒性评估。

Member organizations work together to share data, algorithms, and best practices in the development, application, and validation of digital biomarkers with the ultimate objective of improving the quality and translational relevance of preclinical in vivo research. A future objective for DIVA is to leverage the value of this collaborative effort and help to establish regulatory confidence and acceptance of these innovative capabilities.Inquiries about DIVA and the discovery, development, and adoption of digital biomarkers can be directed to the Digital In Vivo Alliance using the contact information below or at DIVA.bio.SOURCE Digital In Vivo Alliance.

成员组织共同努力共享数字生物标志物开发，应用和验证中的数据，算法和最佳实践，最终目标是提高临床前体内研究的质量和转化相关性。DIVA未来的目标是利用这一合作努力的价值，并帮助建立监管信心和接受这些创新能力。关于DIVA以及数字生物标志物的发现，开发和采用的询问可以使用下面或DIVA.bio.SOURCE digital In Vivo Alliance的联系信息直接发送给数字体内联盟。